Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 7/20 | 0.54 |
| ▸ | ACHE | P22303 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675757 | 0.88 | TRPV1 (0.78) | HDAC1TRPV1SLC2A1MEN1ALDH1A1 | |
| SCHEMBL13675755 | 0.87 | TRPV1 (0.64) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL7605752 | 0.81 | BCHE (0.58) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL7605745 | 0.81 | SLC2A1 (0.73) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL7605747 | 0.81 | SLC2A1 (0.73) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL17693070 | 0.78 | MAPT (0.81) | HDAC1TRPV1MEN1ALDH1A1HPGD | |
| SCHEMBL18544347 | 0.77 | NFE2L2 (0.74) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL18544348 | 0.77 | NFE2L2 (0.74) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13675768 | 0.76 | TRPV1 (0.63) | TRPV1MEN1HPGDKMT2AKDM4E | |
| SCHEMBL18570139 | 0.76 | NFE2L2 (0.76) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1780196-A2 | Pyridine derivatives for use as vanilloid receptor ligands | Amgen, Inc (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | HDAC1 1024/4885HDAC3 1641/4885HDAC4 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.